Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies

Johannes Münch1, Anette Bachmann1, Maik Grohmann2, Christof Mayer1, Michael Kirschfink3, Tom H. Lindner1, Carsten Bergmann2 and Jan Halbritter1

1Division of Nephrology, Department of Internal Medicine, University Clinic Leipzig, Germany, 2Center for Human Genetics, Bioscientia, Ingelheim, Germany and 3Institute of Immunology, University of Heidelberg, Heidelberg, Germany

Abstract

Atypical haemolytic uraemic syndrome (aHUS) may clinically present as acute renal graft failure resulting from excessive activation of the complement cascade. While mutations of complement-encoding genes predispose for aHUS, it is generally thought to require an additional insult (e.g. drugs) to trigger and manifest the full-blown clinical syndrome. Calcineurin inhibitors (CNIs) used for immunosuppression act as potential triggers, especially in the post-transplantation setting. Therefore, CNI-free immunosuppressive regimens may be beneficial. We report on a 58-year-old woman who developed aHUS with acute graft failure within 20 days after renal transplantation. Genetic investigation revealed a homozygous deletion of the CFH-related 1 (CFHR1) and CFHR3 genes in addition to the presence of autoantibodies against complement factor H (CFH). The patient was treated with plasmapheresis and administration of the complement component 5 (C5) antibody eculizumab, and her immunosuppressive regimen was switched from CNI (tacrolimus) to the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor belatacept. Renal graft function recovered and stabilized over an 18-month follow-up period. We describe the successful management of post-transplant aHUS using a CNI-free immunosuppressive regimen based on eculizumab and belatacept. Ideally, adequate molecular diagnostics, performed prior to transplantation, can identify relevant genetic risk factors for graft failure and help to select patients for individualized immunosuppressive regimens.

Key words: atypical haemolytic uraemic syndrome, recurrence, renal transplantation
Introduction

Atypical haemolytic uraemic syndrome (aHUS) is a rare severe condition leading to end-stage renal disease (ESRD) and necessity for renal replacement therapy. In addition, aHUS is also known to occur subsequent to renal transplantation (RTX), either de novo or by way of disease recurrence. It therefore takes a well-considered therapeutic regimen to prevent allograft loss due to uncontrolled activation of the complement system leading to the aHUS hallmark of haemolytic anaemia, thrombocytopenia and thrombotic microangiopathy (TMA). Various mutations in genes encoding the complement system [e.g. complement component 3 (C3)] and its regulators [e.g. complement factor H (CFH), complement factor I (CFI) and membrane cofactor protein (MCP)] are known to predispose for aHUS [1]. The current pathomechanistic understanding, however, suggests a threshold model, where an additional insult (e.g. drugs, infections, pregnancy, graft damage by ischaemia–reperfusion, brain death-related injury) on top of genetic susceptibility is needed for clinical manifestation [2, 3].

Calcineurin inhibitors (CNIs) are one of these potential triggers able to initiate aHUS development. As CNIs are part of the standard immunosuppression after RTX, the question arises whether a CNI-free regimen may be beneficial in selected patients with recurrent or de novo aHUS. In this context, we report the case of a patient with post-transplant aHUS based on a homozygous deletion of complement factor H related 1 (CFHR1) and complement factor H related 3 (CFHR3) and concomitant development of CFH autoantibodies, who was effectively treated with a CNI-free, long-term immunosuppressive regimen, based on eculizumab and belatacept.

Case report

A 58-year-old woman from Greece with a history of > 20 years of chronic kidney disease of unknown origin since her mid-30s received her first deceased kidney transplantation at 48 years of age. Concomitant diseases included hypothyroidism, repeated thrombotic occlusions of her dialysis shunt and a transient ischaemic attack at the age of 41 years. Family history regarding inherited kidney diseases, thromboembolic events and/or malignancy was unremarkable. The patient developed a rapid and irreversible graft failure 18 months after her first kidney transplantation. Diagnostic kidney biopsy revealed TMA in the transplanted kidney, interpreted as potentially CNI-associated as tacrolimus was part of her immunosuppressive regimen.

After another 10 years on haemodialysis, a second deceased RTX was performed under continuous control of haemolytic parameters and complement factors. Despite absence of haemolysis and complement consumption over the first 2 weeks after RTX, onset of graft function was delayed. Subsequently, the patient presented with reduction of urinary volume and rising serum creatinine levels of > 300 μmol/L estimated glomerular filtration rate according to chronic kidney disease epidemiology collaboration (eGFR CKD-EPI) 12 ml/min/1.73 m² (Figure 1). On Day +21, laboratory findings finally revealed both a Coombs-negative haemolytic anaemia (haemoglobin 4.9 mmol/L, platelets 93 × 10⁹/L, haptoglobin <0.1 g/L, fragmentocytes 1%, lactate dehydrogenase 10.5 mmol/L) and consumption of complement factors [C3 0.83 g/L, ref. range 0.9–1.7; complement component 4 (C4) 0.07 g/L, ref. range 0.18–0.49] representing clinical recurrence of aHUS. Accordingly, a subsequent kidney biopsy showed pre-glomerular and intra-glomerular TMA. Triggering infections, especially Shiga toxin-producing bacteria, streptococcus and CMV were not detected.

Complement analysis revealed increased levels of soluble complex of complement component 5b and component 9 (C5b-9) >320 ng/mL, also known as the soluble form of the membrane attack complex (MAC), and CFH autoantibodies (IgG anti-CFH 74 U/mL; ref. range <60 U/mL; method ELISA). Specific mutation analysis, using a targeted complement gene panel (including ADAMTS13, C3, CFB, CFD, CFH, CFHR1, complement factor H related 2 (CFHR2), CFHR3, CFHR5, CFI, DGRE, MCP, MMACHC and THBD), yielded a homozygous deletion of the CFHR1 and CFHR3 genes, which was confirmed by multiplex ligation-probe amplification (Figure 2).

Discussion

Post-transplant aHUS, regardless of whether de novo or recurrent, is a severe complication of RTX, posing an imminent risk of graft loss. The underlying mechanism constitutes an excessive activation of the complement system, which leads to endothelial damage, microthrombosis and ultimate impairment of renal function. Various mutations of complement-encoding genes associated with aHUS have been described. Apart from the established aHUS-susceptibility genes CFH and MCP (CD46 molecule), the so-called ‘regulator of complement activation locus (RCA)’ on chromosome 1 also harbours five related homologues, which was conﬁrmed by multiplex ligation-probe amplification (Figure 2).

Belatacept/eculizumab in post-transplant aHUS
Fig. 1. Course of disease: diagram showing laboratory values (serum creatinine, platelets, haemoglobin, haptoglobin) and immunosuppressive therapy over 18 months. Initiation of belatacept is indicated by vertical blue line ('1') and was given as follows: 750 mg belatacept weekly for 3 weeks, followed by a 4-weekly administration ('2').

Initiation of eculizumab is indicated by vertical dark green line and was administered as follows: 900 mg eculizumab weekly for 4 weeks, followed by 1200 mg eculizumab maintenance 2-weekly ('3').

('4') Discontinuation of eculizumab therapy after 19 weeks post-RTX resulted in rising serum creatinine and recurring haemolytic anaemia; however, re-initiation of eculizumab therapy ('5') led to prompt response and subsequent haematological remission. Horizontal lines denote upper (creatinine)/lower range (platelets, haemoglobin, haptoglobin) of respective reference levels.
aHUS post-transplant and frequent graft failure [10, 11]. CFH autoantibodies were found to be directed against the C-terminal binding domain of CFH that is necessary for interaction with glycosaminoglycans and C3b [4]. It was further hypothesized that microbial proteins are able to induce a CFH neoepitope through conformational change, which results in CFH autoantibody production upon deletion of CFHR1 [4]. By interference with C3b binding, the presence of CFH antibodies leads to decreased inhibition of C3b on the alternative pathway [12, 13]. Taken together, the CFHR1/CFHR3 deletion constitutes a risk allele for development of CFH antibodies, which consecutively results in excessive activation of the complement system, via deactivation of CFH, an important inhibitory regulator of the alternative pathway (Figure 2). The combination of both conditions, CFH antibodies and a homozygous CFHR1/CFHR3 deletion, represents a unique subgroup of complement-mediated aHUS, sometimes referred to as DEAP-HUS (deficiency of CFHR plasma proteins and autoantibody-positive form of haemolytic uraemic syndrome) [14]. In a German cohort of children and adults, 11% of aHUS cases presented with CFH autoantibodies [8]. However, there is no epidemiologic data regarding frequency of DEAP-HUS in a Greek population. In our patient, CFH autoantibody levels were only measured after detection of the homozygous CFHR1/CFHR3 deletion, a unique subgroup of complement-mediated aHUS, sometimes referred to as DEAP-HUS (deficiency of CFHR plasma proteins and autoantibody-positive form of haemolytic uraemic syndrome) [14]. In a German cohort of children and adults, 11% of aHUS cases presented with CFH autoantibodies [8]. However, there is no epidemiologic data regarding frequency of DEAP-HUS in a Greek population. In our patient, CFH autoantibody levels were only measured after detection of the homozygous CFHR1/CFHR3 deletion. Although eculizumab therapy and plasmaphereses were already initiated, antibody titres were still found to be elevated. In contrast, retrospective measurements from previous time points, such as 6 months after first allograft failure and immediately before second transplantation, did not show elevated CFH antibody titres, supporting the triggering role of CNIs after transplantation and point to the value of CFH antibody monitoring in the course of disease.

CNIs are routinely used as immunosuppressive agents after RTX and their role as triggers for aHUS is discussed controversially [2, 15, 16]. By inducing endothelial damage, however, CNIs are able to activate the complement cascade and may even provoke an uncontrolled activation with extensive endothelial damage through formation of the so-called MAC, leading to microthrombosis, haemolytic anaemia and organ failure [17]. Eculizumab, an inhibitor of C5 cleavage and consecutive MAC formation, is an approved therapeutic option to stop uncontrolled complement activation and can be combined with plasmapheresis [18, 19]. The timely initiation of eculizumab is crucial in order to prevent progressive damage to the graft [20]. Because of missing data, recommendations for the duration of eculizumab therapy beyond clinical and haematological remission are vague; a lifelong treatment, however, may be necessary for patients with a robust genetic susceptibility, especially after RTX. Regarding its endothelial toxicity and potency of complement activation, a CNI-free immunosuppressive regimen might be favourable for long-term management of patients at risk. However, administration of mechanistic target of rapamycin (mTOR) inhibitors can itself induce TMA after RTX and recent registry data demonstrates an increased prevalence of aHUS recurrence under mTOR-based regimens [21, 19]. Therefore, belatacept, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) Ig-fusion protein blocking T-cell co-stimulation, offers an attractive alternative as a sufficient immunosuppression for reducing the risk of graft rejection. Recently, the 7-year follow-up data on belatacept in RTX recipients confirmed the previously reported positive outcome of superior kidney function with similar safety profile when compared with a CNI-based protocol with cyclosporine A [22]. Just recently, successful long-term management of de novo post-transplant aHUS with a tailored eculizumab–belatacept combination, substituting tacrolimus, has been reported for the first time, although merely heterozygous for the CFHR1/CFHR3 gene deletion [23].
The downside of this regimen, however, is the high cost of these two intravenously administered drugs (eculizumab and belatacept), confining it to selected aHUS patients at risk. In case of acute allograft failure, aHUS should be generally considered as a differential diagnosis and has to prompt timely investigations and therapeutic consequences. As knowledge of the causative renal disorder is indispensable for risk assessment and planning of RTX, we recommend the consideration of complement analysis and targeted mutation analysis in patients with ESRD of unknown origin awaiting RTX. The presented case illustrates the consequences of delayed diagnostics, as a comprehensive genetic workup prior to second kidney transplantation would have allowed us to better estimate the individual genetic susceptibility and to consequently adapt the immunosuppressive regimen in order to prevent aHUS recurrence.

Informed consent
The described patient provided written informed consent.

Conflict of interest statement
The authors declare no conflicts of interest. However, J.H.

References
1. Vieira-Martins P, El Sissy C, Bordereau P et al. Defining the genetics of thrombotic microangiopathies. Transfus Apher Sci 2016; 54: 212–219
2. Zuber J, Le Quintrec M, Morris H et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev 2013; 27: 117–125
3. Naesens M, Li L, Ying L et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009; 20: 1839–1851
4. Bhattacharjee A, Reuter S, Tjojn et al. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease. J Biol Chem 2015; 290: 9500–9510
5. Heinen S, Hartmann A, Lauer N et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009; 114: 2439–2447
6. Hughes AE, Orr N, Esfandiary H et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006; 38: 1173–1177
7. Xie J, Kiryukh K, Li Y et al. Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol 2016; 27: 3187–3194
8. Józsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512–1514
9. Dragon-Durey MA, Blanc C, Marliot F et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447–450
10. Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22: 704–712
11. Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med 2014; 1: 52
12. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115: 379–387
13. Hofer J, Janecke AR, Zimmerhackl LB et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013; 8: 407–415
14. Skerka C, Zipfel PF, Müller D et al. The autoimmune disease DEAP-hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 625–632
15. Zuber J, Le Quintrec M, Sberro-Soussan R et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7: 23–35
16. Le Quintrec M, Lionnet A, Kamar N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8: 1694–1701
17. Schwimmer J, Nadasdy TA, Spitalnik PF et al. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41: 471–479
18. Alachkar N, Bagnasco SM, Montgomery RA. Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft. Transplant Int 2012; 25: e93–e95
19. Le Quintrec M, Zuber J, Moulin B et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013; 13: 663–675
20. Walle JV, Delmas Y, Ardissino G et al. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2016; 30: 127–134
21. Sartelet H, Toupance O, Lorenzato M et al. De novo atypical hemolytic uremic syndrome. Transplantation 2011; 91: 1169–1175
22. Vincenti F, Rostaing L, Grinyo J et al. Eculizumab for the prevention and management of atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22: 704–712
23. Dedhia P, Govil A, Mogilishetty G et al. Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report. Transplant Proc 2017; 49: 188–192